13h
Pharmaceutical Technology on MSNEC approves Otsuka and Lundbeck’s Rxulti for schizophreniaThe decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.
Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...
Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...
The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...
Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock a sizeable new ...
Otsuka America Pharmaceutical is continuing its work to provide support to and advocate for family caregivers. | Otsuka ...
Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results